Study identifier:NIS-NES-DUM-2008/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective observational study about progress of subjective well-being sensation in schizophrenic patients
schizophrenia
-
No
-
All
320
Observational
18 Years - 65 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6. The primary objective is to asses evolution of subjective well-being and depressive symptoms in schizophrenic patients for six months after an acute episode treated in outpatient psychiatric units. The primary endpoint is: Total score in Subjective Well-being under Neuroleptic treatment (SWN-K) and Calgary Depression Rating Scale (CDRS) scales in assessment after 6 months vs baseline. Secondary objectives include: To evaluate the relationship between subjective well-being and psychopathology, subjective clinical global impression, adverse events and compliance of treatment. Also to compare the clinical global impression of psychiatrist and patient. In addiction to know the clinical, social and demographic factors involve in the subjective well-being and patient clinical global impression.
Location
Location
Adaia, Valencia, Spain
Location
Adeje, Tenerife, Spain
Location
Alcala de Guadaira, Sevilla, Spain
Location
Alcala de Henares, Madrid, Spain
Location
Alcala La Real, Jaen, Spain
Location
Alcoy, Alicante, Spain
Location
Alicante, Alicante, Spain
Location
Almansa, Albacete, Spain
Arms | Assigned Interventions |
---|---|
1 Schizophrenic patients with a acute episode treated in outpatients clinics | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.